Menopause is one of the milestones and one of the most delicate in a woman's life. Hormonal therapy is often needed to counteract its symptoms and consequences , which on the one hand relieves the symptoms and on the other, unfortunately, has a series of collateral. In particular, it seems that hormonal therapies accentuate the risk of developing breast cancer . In an attempt to stem the problem, researchers at Yale University are experimenting with an innovative combination of hormones. Estrogens, usually combined with progesterone, are administered together with SERMs, which replace progestins. SERMs, Selective estrogen receptor modulators, in simple words are drugs able to act on estrogen receptors and to control the action of the latter, avoiding excessive stimulation of the endometrial and mammary cells. As stated by Dr. Taylor this research could be the springboard to improve the status of women in menopause, currently everything is in the embryonic stage, the research is still within the walls of the laboratories, but continues thanks to funding from the Women's Health Research Institute. As in everything, all that remains is to wait. Source and more information
You may also like
MOC, Computerized Bone Mineralometry for osteoporosis
X-ray computerized bone mineralometry (abbreviated as MOC ) represents the current method of reference in the diagnosis of osteoporosis , successfully used at the polyclinic of Milan and in other Italian hospitals. MOC is based on the principle of photonic absorptiometry: a thin beam of X-rays passing through the tissues is absorbed in proportion to… Continua a leggere MOC, Computerized Bone Mineralometry for osteoporosis
Aclasta against osteoporosis and fractures
Novartis publishes the results of the first study performed on Aclasta , an osteoporosis drug in patients with hip fractures. It has been seen that administering Aclasta once a year prevents new fractures by 35% and improves life in a certain sense. In fact, it would seem that in the group of patients analyzed the… Continua a leggere Aclasta against osteoporosis and fractures